ITGB6 and neoplasm: The sigvotatug vedotin construct links an ITGB6-directed monoclonal antibody to the cytotoxic payload MMAE via a cleavable linker, enabling selective internalization and microtubule disruption in ITGB6-expressing tumor cells [143].